FHIR IG analytics| Package | uk.nhsengland.genomics.r4 |
| Resource Type | Observation |
| Id | Observation-GenomicTherapeuticImplication-Example.json |
| FHIR Version | R4 |
No resources found
No resources found
No narrative content found in resource
{
"resourceType": "Observation",
"id": "Observation-GenomicTherapeuticImplication-Example",
"meta": {
"profile": [
"http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/therapeutic-implication",
"http://hl7.eu/fhir/laboratory/StructureDefinition/Observation-resultslab-eu-lab"
]
},
"status": "final",
"category": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/observation-category",
"code": "laboratory"
}
]
},
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0074",
"code": "GE"
}
]
}
],
"code": {
"coding": [
{
"system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
"code": "therapeutic-implication"
}
]
},
"subject": {
"reference": "Patient/Patient-PheobeSmitham-Example"
},
"effectiveDateTime": "2023-09-16",
"performer": [
{
"identifier": {
"system": "https://fhir.nhs.uk/Id/ods-organization-code",
"value": "R0A"
}
}
],
"derivedFrom": [
{
"reference": "Observation/Observation-GenomicsVariantSLC52A2-Example"
}
],
"component": [
{
"code": {
"coding": [
{
"system": "http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs",
"code": "therapeutic-implication",
"display": "Therapeutic Implication"
}
]
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://loinc.org",
"code": "LA9661-5",
"display": "Presumed responsive"
}
]
}
},
{
"code": {
"coding": [
{
"system": "http://loinc.org",
"code": "51963-7",
"display": "Medication assessed"
}
]
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "438481000124108",
"display": "Riboflavin supplement"
}
]
}
}
],
"note": [
{
"text": "High dose riboflavin supplementation has been reported to ameliorate the progression of this disorder (Foley et al 2014 PMID22740598)"
}
]
}